p53 deficiency resulted in enhanced IGF-1R signaling pathway inhibition by metformin in lung adenocarcinoma cells

Wei Dong; Yunxia Zhao; Hongxin Cao; Zhinan Wu; Jiajun Du

doi:10.18632/oncotarget.21566

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 10/06/2017.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

p53 deficiency resulted in enhanced IGF-1R signaling pathway inhibition by metformin in lung adenocarcinoma cells

Wei Dong, Yunxia Zhao, Hongxin Cao, Zhinan Wu and Jiajun Du _

Wei Dong1, Yunxia Zhao2, Hongxin Cao3, Zhinan Wu1 and Jiajun Du1

1Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

2Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

3Department of Oncology, Shandong University Qilu Hospital, Shandong University, Jinan, China

Correspondence to:

Jiajun Du, email: [email protected]

Wei Dong, email: [email protected]

Keywords: metformin, insulin like growth factor receptor subtype 1 (IGF-1R), p53, anticancer therapy, lung adenocarcinoma cells

Received: April 28, 2017 Accepted: September 20, 2017 Epub: October 06, 2017

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21566

Publication Alerts

Post-Publication Promotion

Publication Discount

Withdrawal Notice

Research Papers:

p53 deficiency resulted in enhanced IGF-1R signaling pathway inhibition by metformin in lung adenocarcinoma cells